Success Metrics

Active Trials
8(80%)

Phase Distribution

Ph phase_3
2
20%
Ph phase_1
7
70%
Ph phase_2
1
10%

Phase Distribution

7

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
7(70.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

10

all time

Status Distribution
Active(10)

Detailed Status

Recruiting8
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
8
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 17 (70.0%)
Phase 21 (10.0%)
Phase 32 (20.0%)

Trials by Status

not_yet_recruiting220%
recruiting880%

Recent Activity

8 active trials
Showing 5 of 10
not_yet_recruitingphase_3

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

NCT07595913
recruitingphase_1

Study of ZGGS34 in Participants With Advanced Solid Tumors

NCT07258121
recruitingphase_1

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

NCT07231445
recruitingphase_1

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

NCT05978284
recruitingphase_1

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

NCT07038096
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07595913Phase 3

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Not Yet Recruiting
NCT07258121Phase 1

Study of ZGGS34 in Participants With Advanced Solid Tumors

Recruiting
NCT07231445Phase 1

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Recruiting
NCT05978284Phase 1

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting
NCT07038096Phase 1

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting
NCT07189455Phase 3

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Recruiting
NCT06283719Phase 1

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Recruiting
NCT06592638Phase 1

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

Recruiting
NCT07024277Phase 2

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Not Yet Recruiting
NCT06440057Phase 1

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Recruiting

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10